Mediworld Middle East

Stereotaxis has achieved a significant milestone with the European CE mark approval for its latest robotic surgery system, GenesisX. This innovative platform, designed for easier installation and commercial scalability, aims to overcome previous challenges related to hospital construction and complex installation processes. GenesisX represents a major advancement in robotic surgery, incorporating smaller magnets, an integrated #robotic base with magnetic shielding, and more sophisticated electronics. This new design simplifies installation by eliminating the need for extensive magnetic shielding in operating room walls and structural anchoring, making it more accessible to hospitals. David Leo Fischel, CEO of Stereotaxis, highlighted the system’s potential to drive commercial growth and address key barriers that have historically impeded sales. “GenesisX allows us to transition from a construction model to a placement model,” Fischel stated. The company has also submitted a 510(k) application to the FDA for U.S. market entry. Despite a challenging first half of the year with a revenue dip, Stereotaxis remains optimistic about future growth, anticipating improved revenue and cash flow in the latter half of the year. The company expects FDA clearance by year-end and is advancing towards regulatory approval for a compatible ablation catheter, Magic. Stereotaxis continues to innovate in the field of robotic surgery, with GenesisX set to redefine market dynamics and enhance patient care through advanced #technology. #RoboticSurgery #MedicalTechnology #GenesisX #Innovation #Stereotaxis #Healthcare #MinimallyInvasive #EndovascularProcedures #FDAApproval #CEMark #MedicalDevices #SurgicalRobotics #HealthcareInnovation #MedicalTechnology #SurgicalAdvancements #HealthcareSolutions #dubai #uae

Exciting Partnership Alert! Mediworld Middle East is thrilled to announce its #media partnership with the Wellness Odyssey 2024, taking place on the 3rd and 4th of September. This groundbreaking event promises to be a journey into the future of wellness, bringing together industry leaders, innovators, and enthusiasts for two days of transformative experiences, insightful discussions, and cutting-edge developments in health and well-being. Designed to connect medical and well-being travel solution providers with pre-qualified corporate buyers from across the globe, The Wellness Odyssey is all about fostering impactful connections through pre-arranged, one-on-one meetings. Attendees will include influential representatives from governmental entities in the Arab world, top insurance companies, multinational corporations, specialized travel agencies, and leading doctors and specialists. Stay tuned for exclusive coverage, expert interviews, and behind-the-scenes insights as we dive deep into the latest trends shaping the wellness landscape. Don’t miss out on this opportunity to be part of the wellness revolution! Mark your calendars and join us on this extraordinary journey! https://lnkd.in/gZnq43TB #WellnessOdyssey2024 #MediworldMiddleEast #HealthAndWellness #dubai #uae #mediapartnership #wellness #event #health #medical #digitial #transformation

DuPont de Nemours (Deutschland) GmbH has successfully closed its acquisition of Donatelle Plastics, Inc. for $313 million as of July 28, marking a significant expansion in its medical device capabilities. This strategic acquisition enhances DuPont’s materials science division, known as New DuPont, as part of the company's ongoing transformation into three independent public entities. Donatelle, based in New Brighton, Minnesota, is renowned for its design, development, and manufacturing of medical components and devices, with expertise spanning cardiac, diagnostics, and orthopedic extremities. This acquisition complements DuPont’s recent purchase of Spectrum Plastics Group, reinforcing its position in the high-growth medical device market. CEO Lori Koch highlighted the strategic importance of the acquisition: “Together, these offerings are expected to enhance our position as a partner of choice for customers in the high-growth medical device field.” Donatelle’s proximity to Medical Alley, a prominent medtech hub, also presents cross-selling opportunities and strengthens DuPont’s ties to major OEMs like Medtronic, Abbott, and Solventum. With over 400 employees and a focus on technologies such as injection molding and liquid silicone rubber processing, Donatelle is expected to generate approximately $75 million in new revenue for DuPont this year. DuPont’s transformation into three distinct entities is progressing, with executive leadership and board appointments for the electronics and water filtration companies anticipated next year. DuPont Donatelle, A DuPont Business #DuPont #MedicalDevices #Acquisition #DonatellePlastics #MaterialsScience #MedicalDeviceMarket #Innovation #Medtech #Healthcare #BusinessGrowth #IndustryNews #Manufacturing #BusinessStrategy #CorporateExpansion #MedicalTechnology #RevenueGrowth

Indica Labs is proud to announce the launch of Lung Macrodissect AI, a groundbreaking tool set to revolutionize slide macrodissection and molecular pathology workflows. This AI-powered solution marks a significant leap forward in integrating artificial intelligence with digital pathology, enhancing efficiency and precision in tumor content assessment and macrodissection. Key Features of Lung Macrodissect AI: Enhanced Accuracy: Quantifies tumor content across entire whole slide images, providing real-time data and reducing subjectivity. Streamlined Workflow: Automates tumor annotation and specimen quality assurance, significantly reducing human error and labor-intensive processes. AI Integration: Deployed in HALO AP, it combines with Xyall’s robotic macrodissectors for a fully automated, audited workflow. Tumor content estimation and macrodissection are crucial yet challenging steps in molecular pathology. Traditional methods can be error-prone and time-consuming. Lung Macrodissect AI addresses these issues by offering precise quantification of tumor cells and generating heatmaps to guide the annotation process. Steven Hashagen, CEO of Indica Labs, states, “Our macrodissection AI models significantly advance the field of molecular pathology. Lung Macrodissect AI is a part of our suite of macrodissection tools, with additional products for colon, breast, and prostate cancers on the horizon.” The tool has already demonstrated its impact through clinical validation, improving consistency in tumor content estimation across pathologists and enhancing overall workflow quality. This innovation is set to transform how pathologists approach macrodissection, making genetic testing more accessible, accurate, and efficient. Read more about this exciting development and how it’s shaping the future of cancer diagnostics! #DigitalPathology #AIinHealthcare #MolecularPathology #CancerResearch #Innovation #IndicaLabs #HealthcareTechnology #Pathology #TumorAnalysis #PrecisionMedicine #LaboratoryAutomation #MedicalAI #dubai #Uae #digital #medtech #Medical #technology

Beckman Coulter Life Sciences and Illumina have partnered to unveil a groundbreaking solution that promises to revolutionize oncology research. Introducing the Illumina TruSight™ Oncology 500 DNA/RNA assay on the Biomek NGeniuS System—a cutting-edge, automated approach designed to deliver faster results with fewer touchpoints. This innovative assay supports comprehensive genomic profiling of tumor samples, detecting critical cancer biomarkers such as single nucleotide variants (SNVs), insertions, deletions, gene amplifications, fusions, and splice events. With the capability to process 4 to 24 libraries in a single batch, this system can handle both high-quality and low-quality FFPE samples, significantly speeding up the library preparation process to less than three days. Key highlights include: Enhanced Automation: From sample preparation to sequencing, achieving precision and efficiency. Reduced Plastic Use: Optimized for lower consumable costs and environmental impact. Accelerated Results: Delivering critical research insights faster and more reliably. Ewan Grant Director of the Biotech Workflow Solutions Business Unit at Beckman Coulter Life Sciences, emphasizes, “The continued collaboration with Illumina aims to accelerate the journey from sample to insight, showcasing our commitment to enabling customers to deliver data quicker and more reliably without the difficulties of manual workflows.” Discover how this new application is set to transform cancer research and enhance diagnostic capabilities. #OncologyResearch #GenomicProfiling #NextGenSequencing #Innovation #BeckmanCoulter #Illumina #LaboratoryAutomation #Biotech #CancerBiomarkers #ResearchInnovation #SequencingTechnology #cancer #research #medtech #uae #dubai #global

Life Sciences Hub Wales is thrilled to unveil a new series of digital case studies showcasing groundbreaking cancer care innovations emerging from Wales. This initiative highlights the pioneering work of #QuicDNA and #CanSense, underscoring the organization's commitment to advancing cancer treatment and detection through cutting-edge technologies. QuicDNA: This project brings together cross-sector partners and funders to amplify the impact of liquid biopsy technology. Offering a non-invasive alternative to traditional tumour biopsies, QuicDNA uses blood tests to accelerate diagnosis and treatment, significantly improving patient outcomes. Craig Maxwell's contributions and fundraising efforts exemplify the spirit of innovation and dedication driving this project. CanSense: Focused on developing a blood-based assay for non-invasive bowel cancer diagnosis, CanSense leverages AI-driven models to detect early signs of colorectal cancer. With bowel cancer being one of the most common and deadly cancers globally, this revolutionary test promises to simplify diagnosis and enhance patient care. Cari-Anne Quinn, CEO of Life Sciences Hub Wales, shares, “Cancer care in Wales is advancing, but challenges remain. By showcasing innovations like QuicDNA and CanSense, we aim to inspire and demonstrate how transformative technologies can revolutionize cancer detection and treatment. Collaboration across health, social care, and industry is key to accelerating these breakthroughs.” #CancerCare #Innovation #LifeSciences #QuicDNA #CanSense #HealthTech #AIinHealthcare #LiquidBiopsy #BowelCancer #EarlyDetection #HealthcareInnovation #LifeSciencesHubWales

Leica Microsystems is proud to introduce the Mateo FL, an advanced AI-powered #digital #fluorescence #microscope designed to elevate cell culture checks in cutting-edge research applications. Combining transmitted light for label-free imaging with multi-channel fluorescence, Mateo FL offers a suite of automated analysis tools to streamline and enhance laboratory workflows. With its modern, compact design and intuitive features, Mateo FL is set to transform how researchers approach cell culture experiments. Key highlights include: #AIPowered Confluency Checks: Streamline your cell culture analysis with precise and automated evaluations. Swift and Accurate Cell Counting: Achieve reliable results in just 5 seconds, saving an average of 15 minutes compared to manual counting. Smart Measurements for Transfection Efficiency: Ensure accurate assessments with minimal effort. Automated Phase Contrast Function: Enhance image acquisition efficiency, reducing manual intervention. James O'Brien VP of Life Sciences and Applied Solutions at Leica Microsystems, emphasizes, “Mateo FL is a smart digital solution that offers unparalleled ease, allowing researchers to accelerate experiments, tackle contamination, and protect data integrity—ensuring consistent, reliable, and reproducible results.” Mateo FL’s compact design also reduces contamination risks by up to 50% and doubles workflow efficiency by capturing both monochrome and color images without the need for device swaps. Built-in audit trails and user management features support FDA 21 CFR Part 11 compliance, making it an ideal choice for secure data tracking in pharmaceutical research. #LeicaMicrosystems #MateoFL #FluorescenceMicroscopy #AIinResearch #CellCulture #ScientificInstrumentation #LabEfficiency #FDACompliance #ResearchInnovation #Microscopy

Paragonix Technologies, Inc., has achieved a significant milestone by reporting the first pediatric liver transplant using the #LIVERguard Donor Liver Preservation System. This groundbreaking procedure was successfully performed by Dr. Deepak Vikraman at Duke University Hospital in Durham, NC. Since its launch in 2022, the LIVERguard system has been utilized in over 300 liver transplant cases across the U.S., marking this as its first application in a pediatric setting. Recent clinical presentations have demonstrated that the LIVERguard system reduces potential post-transplant complications compared to traditional ice storage methods. Data from the GUARDIAN-LIVER global clinical registry, which evaluates the impact of liver preservation and transportation technologies, supports these findings. The LIVERguard system has also revolutionized liver procurement and allocation in the U.S., enabling long-distance procurements from Puerto Rico and Hawaii and facilitating the placement of high-risk donor livers. Dr. Vikraman highlighted the importance of innovative preservation technologies in pediatric care, stating, “New technologies are pushing the boundaries of what was previously possible. By advancing preservation methods, we can expand donor pools and offer young patients a second chance at life.” #OrganTransplant #LiverTransplant #PediatricCare #HealthcareInnovation #TransplantTechnology #ParagonixTechnologies #LIVERguard #DukeUniversity #PatientCare #LifeSavingTechnology

BSF Enterprise, the owner of corneal tissue replacement company Kerato Limited , is thrilled to announce that Kerato has signed a Heads of Terms agreement and research partnership with the Université de Montréal. Kerato and the University of Montreal will combine their tissue engineering expertise to develop an in-situ gelling #cornea, a novel treatment aimed at addressing #cornealdamage and full-thickness perforations. Given that corneas are the most frequently transplanted human tissue worldwide, with around 185,000 procedures annually, this new treatment holds tremendous potential. Unfortunately, 55% of the world’s population lacks access to donor material, leaving an estimated 12.7 million people waiting for a transplant. Kerato's approach involves the use of a synthetic extracellular matrix protein sequence combined with host corneal stromal cells to promote tissue healing. This innovative treatment, administered via injection, is designed to repair damaged tissue without the need for full transplant surgery, thereby simplifying procedures, reducing hospital time, lowering the risk of graft rejection, and cutting costs for healthcare providers—all while improving patient outcomes. The partnership will leverage the successful pre-clinical studies led by May Griffith to advance the prototype corneal treatment through safety and efficacy studies, clinical trials, and regulatory approvals, paving the way for international market entry. To expedite this process and reduce risk, the new approach will first be trialed in the veterinary space, offering animal owners access to complex corneal repair treatments. Sarah Greenhalgh, Managing Director at Kerato Ltd, expressed her enthusiasm: “This partnership with the University of Montreal marks a crucial step forward for Kerato’s corneal regenerative therapy technologies. We are excited to work on a transformative treatment that not only enhances corneal repair but also supports healthcare providers by reducing costs and improving patient outcomes.” #Biotech #TissueEngineering #CornealTherapy #HealthcareInnovation #UniversityofMontreal #KeratoLtd #ResearchPartnership #RegenerativeMedicine #PatientCare #dubai #Uae #Medical #technology #surgery #cornea

C2N Diagnostics is making strides in Alzheimer's diagnosis with the development of its Precivity portfolio, aiming to enhance access to early detection tools through less invasive and more cost-effective blood tests. Recognizing the importance of these advancements, Unilabs, a leading diagnostic services provider with over 13,000 employees, has entered into a multi-year agreement to exclusively distribute C2N's tests across #Europe, #Peru, #SaudiArabia, and the #UAE. The partnership is a significant move toward expanding access to C2N’s innovative PrecivityAD2 test, which has shown impressive diagnostic accuracy of 88% to 92% in a recent study published in JAMA. This blood test dramatically improves diagnostic precision in both primary and secondary care settings, marking a major step forward in the early diagnosis of Alzheimer’s disease. Unilabs is also preparing to run Precivity tests in Europe through a technology transfer plan designed to maintain the same high standards as C2N’s Missouri lab. This collaboration aligns with Unilabs’ commitment to delivering cutting-edge diagnostic solutions globally. #Alzheimers #Diagnostics #HealthcareInnovation #C2NDiagnostics #Unilabs #Precivity #EarlyDiagnosis #Healthcare #Neuroscience #Partnerships